BNP Paribas Financial Markets Buys 101,014 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

BNP Paribas Financial Markets boosted its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 241.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 142,842 shares of the company's stock after buying an additional 101,014 shares during the period. BNP Paribas Financial Markets owned approximately 0.09% of Wave Life Sciences worth $1,767,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in WVE. SG Americas Securities LLC boosted its stake in Wave Life Sciences by 46.1% during the fourth quarter. SG Americas Securities LLC now owns 53,419 shares of the company's stock valued at $661,000 after buying an additional 16,856 shares during the last quarter. KBC Group NV bought a new stake in shares of Wave Life Sciences in the 4th quarter valued at approximately $67,000. Moody Aldrich Partners LLC lifted its stake in shares of Wave Life Sciences by 31.5% in the 4th quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company's stock valued at $4,929,000 after purchasing an additional 95,413 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Wave Life Sciences by 126.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 54,267 shares of the company's stock valued at $671,000 after purchasing an additional 30,276 shares during the last quarter. Finally, James J. Burns & Company LLC lifted its stake in shares of Wave Life Sciences by 11.0% in the 4th quarter. James J. Burns & Company LLC now owns 111,111 shares of the company's stock valued at $1,374,000 after purchasing an additional 11,000 shares during the last quarter. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Trading Down 2.3%

Shares of NASDAQ WVE traded down $0.14 during midday trading on Friday, hitting $5.95. The company's stock had a trading volume of 1,011,246 shares, compared to its average volume of 1,287,925. The business's 50 day moving average is $7.01 and its two-hundred day moving average is $10.63. Wave Life Sciences Ltd. has a 12-month low of $4.25 and a 12-month high of $16.74. The firm has a market cap of $917.10 million, a P/E ratio of -5.36 and a beta of -0.92.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The business had revenue of $9.18 million during the quarter, compared to analysts' expectations of $11.65 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. On average, analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Wave Life Sciences in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective for the company. Wall Street Zen lowered Wave Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Wedbush assumed coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.17.

Insiders Place Their Bets

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares in the company, valued at $157,443.55. This trade represents a 39.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.